Skip to main content
TipRanks
Go Ultimate75% OFF

GENOVA Inc. (9341) AI Stock Analysis

2 Followers
JP:9341

GENOVA Inc.

(TSE/TYO:9341)

Select Model
Rating:59Neutral
Price Target:JPY 606.00▲(7.64% Upside)
Action:reiterated
Date:11/18/26

GENOVA Inc. achieves a moderate overall score, buoyed primarily by a highly attractive 5.17% dividend yield and a fortress balance sheet with minimal debt. However, these strengths are heavily clouded by severe recent contractions in operating profitability and cash flow generation, which present notable long-term risks. Furthermore, bearish technical momentum indicates current market hesitation, making it a mixed proposition requiring stabilization in profit margins before a higher rating can be justified.

Positive Factors
Sustained Revenue ExpansionRevenue increased about 24% in 2026 and the company has extended a multi-year expansion trend. Sustained top-line growth indicates continuing demand and market opportunity, providing a durable base for future operating leverage if profitability can recover.
Negative Factors
Severe Margin CompressionThe sharp decline in gross margin and compression of operating and net margins weaken the quality and predictability of earnings. Unless margins stabilize, strong revenue growth may translate into limited profit growth and leave the business more exposed to cost pressure.

GENOVA Inc. (9341) vs. iShares MSCI Japan ETF (EWJ)

-10%-5%0%5%10%15%20%25%30%JP:9341-1.25%EWJ+11.03%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 9.61B
Dividend Yield
5.33%
Average Volume (3M)
62.88K
Price to Earnings (P/E)
14.9
Beta (1Y)
0.64
Revenue Growth
46.39%
EPS Growth
12.53%
Country
Japan
Employees
529
Sector
Healthcare
Sector Strength
51
Industry
Software - Application

GENOVA Inc. Business Overview & Revenue Model

Company Description

Operating within Japan, GENOVA, Inc. focuses on the digital healthcare market, providing both medical platform services and smart clinic solutions. Its offerings include Medical Doc, a comprehensive online platform that distributes diverse content, s...

GENOVA Inc. Financial Statement Overview

Summary

GENOVA Inc. presents a polarized financial profile. Positives include strong top-line revenue growth and a highly resilient balance sheet with a minimal debt-to-equity ratio of 0.11. However, this is heavily offset by a severe deterioration in operating margins (dropping to 3.5%), an 80% plunge in net income, and a concerning shift toward negative free cash flow.

Income Statement

45Neutral

Balance Sheet

85Very Positive

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue12.77B11.57B10.01B8.68B6.51B4.80B
Gross Profit6.76B6.47B7.38B6.55B4.79B3.50B
EBITDA513.44M543.85M2.11B2.38B1.79B1.09B
Net Income623.48M275.40M1.41B1.73B1.26B686.27M
Balance Sheet
Total Assets11.31B10.26B8.53B8.20B5.41B2.82B
Cash, Cash Equivalents and Short-Term Investments5.08B5.32B5.87B5.97B3.86B1.65B
Total Debt1.77B735.71M20.84M377.78M28.25M163.50M
Total Liabilities5.16B3.36B1.53B2.16B1.37B1.33B
Stockholders Equity6.15B6.90B7.00B6.04B4.04B1.49B
Cash Flow
Free Cash Flow0-46.98M1.06B1.77B1.11B513.36M
Operating Cash Flow053.85M1.19B1.82B1.20B623.77M
Investing Cash Flow0-809.75M-275.93M-94.24M-113.45M-179.06M
Financing Cash Flow0199.63M-1.01B376.82M1.13B59.88M

GENOVA Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price563.00

Price Trends

50DMA598.72Negative
100DMA608.80Negative
200DMA588.79Negative

Market Momentum

MACD-9.46Positive
RSI38.63Neutral
STOCH34.98Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9341, the sentiment is Negative. The current price of 563.00 is below the 20-day moving average (MA) of 579.25, below the 50-day MA of 598.72, and below the 200-day MA of 588.79, indicating a bearish trend. The MACD of -9.46 indicates Positive momentum. The RSI at 38.63 is Neutral, neither overbought nor oversold. The STOCH value of 34.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9341.

GENOVA Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:9341 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:9341JP:934159NeutralJPY 10.04B14.89―5.33%46.39%12.53%
JP:4480JP:448054NeutralJPY 56.52B32.9911.30%―21.01%10.15%
JP:9218JP:921852NeutralJPY 7.94B29.89―1.32%34.18%-32.29%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4438JP:443847NeutralJPY 2.16B-4.71――34.13%35.54%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%JP:9341JP:4480JP:4438JP:9218JP:366ADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:9341 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:9341GENOVA Inc.563.000.500.09%
JP:4480Medley, Inc.1777.00-873.00-32.94%
JP:4438Welby Inc.253.00-42.00-14.24%
JP:9218Mental Health Technologies Co. Ltd.756.00-92.19-10.87%
JP:366AWellness Communications Corporation1062.00-168.66-13.70%

GENOVA Inc. Corporate Events

GENOVA Reports Six-Month Results With Sales of ¥7,809 Million

Nov 13, 2026

GENOVA Inc. reported consolidated net sales of ¥7,809 million for the six months ended Sept. 30, 2026, up 57.0% year over year. Operating profit was ¥46 million, ordinary profit ¥69 million and profit attributable to owners of the parent ¥358 million...

GENOVA Acquires “Karada ni Iikoto” Healthcare Media Business to Boost Medical Platform

Sep 11, 2026

GENOVA Inc. has agreed to acquire the “Karada ni Iikoto” healthcare media business from Central Medience Co., Ltd. for an expected 51 million yen in cash, obtaining contracted editorial services, sponsored content, and PR functions centered on the pl...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026